UBS Upgrades GE HealthCare: $88 Price Target Planby Mark Eisenberg 12.02.2024UBS upgrades GE HealthCare Technologies to Neutral, raises price target to $88. Positive outlook for company's margin improvement and revenue ...
Collins Aerospace Elevates U.S. Air Force with ATNAVICSby Terry Bingman 12.02.2024Collins Aerospace, a business unit of RTX, delivers mobile air traffic control systems to the U.S. Air Force. These systems ...
BofA Initiates PSBD Coverage: Neutral With 12% Upsideby Mark Eisenberg 12.02.2024BofA Securities initiates coverage on Palmer Square Capital BDC with a Neutral rating. Market valuation reflects risks and rewards, potential ...
Bitcoin Wobbles, Immutable Soars Amid Crypto Shuffle: Market Updateby John Darbie 12.02.2024Bitcoin and Ethereum remain steady, with slight declines but still above key levels. Some cryptocurrencies gained traction while others faced ...
Abacus Life Offers $25M Notes, Secure Top Market Spotby Mark Eisenberg 12.02.2024Abacus Life has announced the pricing of a $25 million public offering to refinance debt. With strong financial growth, the ...
Piper Sandler Bullish on Cass Post-Earnings Surgeby Mark Eisenberg 12.02.2024Investment firm Piper Sandler has upgraded Cass Information Systems' rating to Overweight and increased its price target. Analysts are optimistic ...
TOP Financial’s Rollercoaster: Surge to Slide Volatilityby Terry Bingman 12.02.2024Shares of TOP Financial Group Ltd. tumbled 12.2% in premarket trading today after a surge on Friday. The stock's volatility ...
Jefferies Upgrades Lincoln National: Turnaround Ahead?by Terry Bingman 12.02.2024Jefferies upgrades Lincoln National to "Hold" rating, raising price target to $26.00. Upgrade based on expected RBC ratio and strategy ...
W.P. Carey Stock: Buy or Sell After Dip?by Mark Eisenberg 12.02.2024W. P. Carey & Co. faces downgrade and concerns after stock decline due to credit issues and non-renewal, but oversold ...
Tonix Pharma’s Potential PTSD Cure: A Game-Changer?by Mark Eisenberg 12.02.2024Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...